Archives

  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Dual-Mode ...

    2026-01-23

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Dual-Mode Reporter for Enhanced Mammalian Expression

    Executive Summary: EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is a chemically modified mRNA enabling simultaneous fluorescent and bioluminescent readouts in mammalian cells using Cap1 capping and 5-methoxyuridine triphosphate (5-moUTP) modification to suppress innate immune activation (APExBIO). The Cy5 fluorophore (excitation/emission: 650/670 nm) allows for direct visualization, while the encoded Photinus pyralis luciferase catalyzes ATP-dependent oxidation of D-luciferin, producing chemiluminescence at ~560 nm (Hattori & Shimizu, 2024). Cap1 structure and poly(A) tail further support enhanced translation and stability, outperforming Cap0 mRNAs. These features make the product ideal for mRNA delivery, translation efficiency assays, cell viability studies, and in vivo imaging. The product must be handled under RNase-free conditions and stored at -40°C or below to maintain integrity (APExBIO).

    Biological Rationale

    Messenger RNA (mRNA) is a single-stranded RNA that encodes proteins, serving as a direct template for translation in the cytoplasm (Hattori & Shimizu, 2024). For mammalian systems, efficient mRNA delivery requires chemical modifications to overcome rapid degradation and innate immune activation. The Cap1 structure, enzymatically added post-transcription, mimics native eukaryotic mRNA, increasing translation efficiency and reducing immunogenicity compared to Cap0 capped mRNAs (EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Reporter). Incorporation of modified nucleotides like 5-moUTP further diminishes recognition by toll-like receptors, suppressing interferon response and enhancing protein output (EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Reporter). Fluorophore labeling (Cy5) enables direct tracking of mRNA uptake and subcellular localization, facilitating optimization of delivery vectors. The encoded firefly luciferase reporter offers sensitive, quantifiable readouts for translation studies and in vivo imaging (Illuminating In Vivo Imaging).

    Mechanism of Action of EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is synthesized via in vitro transcription with incorporation of 5-moUTP (a 5-methoxy modification of uridine) and Cy5-UTP at a 3:1 ratio. The Cap1 structure is enzymatically added after transcription using Vaccinia virus capping enzyme (VCE), GTP, S-adenosylmethionine, and 2'-O-methyltransferase, yielding a transcript optimized for eukaryotic translation initiation. The Cy5 label enables real-time fluorescence tracking without significantly impacting translation efficiency. The poly(A) tail enhances ribosome recruitment and mRNA stability. Upon delivery into mammalian cells (e.g., via cationic lipid lipoplexes), the mRNA is translated by ribosomes, producing firefly luciferase, which catalyzes an ATP-dependent bioluminescent reaction with D-luciferin. This dual-mode detection (fluorescent and bioluminescent) allows for both qualitative visualization and quantitative measurement of mRNA uptake and translation (Hattori & Shimizu, 2024).

    Evidence & Benchmarks

    • Cap1-capped mRNAs demonstrate significantly higher translation efficiency in mammalian cells compared to Cap0-capped mRNAs (Hattori & Shimizu, 2024).
    • 5-moUTP modification reduces innate immune activation as measured by decreased interferon-β induction (EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Reporter).
    • Cy5-labeled mRNA enables efficient visualization of intracellular mRNA uptake without impairing luciferase expression (Illuminating In Vivo Imaging).
    • Firefly luciferase mRNA delivered with cationic lipids via the MEI method yields high protein expression in HeLa, PC-3, and HepG2 cells, with cell viability exceeding 80% in optimized conditions (Hattori & Shimizu, 2024).
    • EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) maintains activity after shipping on dry ice and storage at -40°C for up to several months (APExBIO).

    This article extends the mechanistic context provided in Dual-Mode Mammalian Reporter by detailing the molecular design and application-specific evidence for the R1010 kit.

    Applications, Limits & Misconceptions

    Core Applications:

    • Translation efficiency assays in mammalian cells using dual-mode (fluorescent and bioluminescent) detection.
    • Optimization of mRNA delivery methods, such as cationic lipid-based lipoplexes.
    • Cell viability and toxicity studies with real-time assessment of mRNA uptake.
    • In vivo bioluminescence imaging for tracking expression and biodistribution.

    Common Pitfalls or Misconceptions

    • EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is not intended for clinical or therapeutic use; it is strictly for research applications (APExBIO).
    • The Cy5 label does not interfere with translation, but excessive labeling (>25% Cy5-UTP) may reduce protein yield (EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Reporter).
    • RNase contamination during handling can rapidly degrade the mRNA; always use RNase-free conditions.
    • The R1010 kit requires storage at -40°C or below; repeated freeze-thaw cycles can reduce activity.
    • Luciferase activity depends on the presence of ATP and D-luciferin; omission of substrates will result in no bioluminescence.

    Workflow Integration & Parameters

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is supplied at ~1 mg/mL in 1 mM sodium citrate buffer, pH 6.4. For transfection, recommended protocols include forming mRNA lipoplexes using cationic lipids such as TC-1-12 and DOPE at optimized charge ratios (3:1 or 4:1, +:-), with the MEI method providing higher efficiency and lower cytotoxicity than TFH (Hattori & Shimizu, 2024). Fluorescence (Cy5: 650/670 nm) provides rapid assessment of cellular uptake, while luciferase assays quantify translation output (emission: ~560 nm). Product integrity is maintained by shipping on dry ice and storing at or below -40°C. For best results, handle on ice and avoid repeated freeze-thaw cycles. For troubleshooting and protocol insights, see Enhancing Cell Assays with EZ Cap™ Cy5 Firefly Luciferase mRNA, which offers scenario-specific guidance; this article expands on benchmark data and dual-mode readout integration.

    Conclusion & Outlook

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) from APExBIO sets a new standard for dual-mode, low-immunogenicity mRNA reagents in mammalian expression systems. The combination of Cap1 capping, 5-moUTP modification, and Cy5 labeling delivers robust translation, real-time uptake visualization, and sensitive bioluminescent quantification. These properties enable precise optimization of mRNA delivery, facilitate advanced translation efficiency assays, and support in vivo imaging workflows. Ongoing developments in mRNA engineering and delivery will further expand the versatility and impact of such dual-mode reagents in functional genomics, cell-based screening, and preclinical research.